BUREAU-VERITAS
4.9.2024 08:01:32 CEST | Business Wire | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services, today announced the acquisition of ArcVera Renewables, a specialized provider in finance-grade consulting and technical services for wind, solar, and battery storage projects worldwide. This acquisition is aligned with Bureau Veritas LEAP | 28 strategy to create a new stronghold in the fast-growing sector of renewables.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903622866/en/
Hinda Gharbi, CEO Bureau Veritas (Photo: Business Wire)
Bureau Veritas contributes to the energy transition by providing the power sector customers end-to-end solutions to meet the immediate and future challenges of developing and operating renewable assets. This acquisition will expand Bureau Veritas’s capabilities, primarily in North America, to support landowners, developers and owners, and investors in delivering their wind and solar farm projects.
ArcVera Renewables provides customers with advanced technical site and resources assessments, and consultancy during the development and operations stages of utility-scale renewables projects. The company’s engineers, technical and subject matter experts support clients with risk reduction and ensure optimal asset performance. Since its inception, ArcVera Renewables has supported 9GW of solar projects in North and South America and has evaluated projects now representing 93,000 MW of wind capacity in the United States. ArcVera Renewables delivered revenues of €6.5 million in 2023 and is headquartered in Golden, Colorado.
“The acquisition of ArcVera Renewables supports our LEAP | 28 strategy, aimed at expanding our services and strengthening our position as a leader in the renewables and power generation sector,” said Hinda Gharbi, Chief Executive Officer of Bureau Veritas. “ArcVera Renewables has built a reputation for excellence in due diligence and operational verification on renewable projects. Their expertise will be a valuable addition to Bureau Veritas’s portfolio of capabilities for the energy transition services. I warmly welcome all new colleagues from ArcVera Renewables to Bureau Veritas.”
“We saw how the broad and deep technical prowess of Bureau Veritas would be a powerful catalyst for ArcVera Renewables” added Greg Poulos, CEO of ArcVera Renewables. “Since inception, our goal has been to accelerate the clean transformation of the world’s energy sector by delivering trustworthy, valuable, detailed, and independent technical analysis for the success of our clients. Joining Bureau Veritas is a leap forward in achieving this goal and is likewise transformational for the ArcVera team and its growing global renewable energy client-base.”
***
About Bureau Veritas
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress.
With a vision to be the preferred partner for its customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 83,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40 ESG, CAC Next 20, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com, and follow us on LinkedIn.
About ArcVera Renewables
ArcVera Renewables provides finance-grade consulting and technical services for wind, solar and storage projects worldwide. For the last four decades, ArcVera Renewables has been dedicated to delivering next-generation innovation in renewable energy to meet the needs of landowners, project developers, investors, project owners and operators globally. ArcVera Renewables provides technically sound and accuracy-driven technical services, including prospecting and resource assessment, independent technical and financial engineering, as well as plant optimization, operations and repowering. Subsidiary offices are located in India, Brazil, and South Africa, serving all continents.
For more information, visit www.arcvera.com, and follow us on LinkedIn.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903622866/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom